BioNexus Gene Lab (BGLC) Short-term Investments (2020 - 2026)

BioNexus Gene Lab (BGLC) has 5 years of Short-term Investments data on file, last reported at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments changed N/A year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (changed N/A YoY), and the FY2025 full-year result was $1.7 million, down 40.72% from the prior year.
• Short-term Investments rose to $2.6 million in Q1 2026, from $1.7 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $2.8 million in Q4 2024 to a low of $1.7 million in Q4 2025.
• A 3-year average of $2.2 million and a median of $2.2 million in 2025 frame the typical range for Short-term Investments.
• Peak annual rise in Short-term Investments reached 40.72% in 2025, while the deepest fall reached 40.72% in 2025.
• Tracing BGLC's Short-term Investments over 3 years: stood at $2.8 million in 2024, then slumped by 40.72% to $1.7 million in 2025, then soared by 58.63% to $2.6 million in 2026.
• Business Quant data shows BGLC's Short-term Investments at $2.6 million in Q1 2026, $1.7 million in Q4 2025, and $1.7 million in Q3 2025.